Sanofi has struck a deal to buy Kiadis for €308 million ($358 million). The takeover will give Sanofi full control of an off-the-shelf natural killer (NK) cell platform it is already using to try to enhance its multiple myeloma drug Sarclisa.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,